prevention organ allograft rejection specific janus kinase inhibitor
requirement signaling multiple cytokines janus kinase jak3 excellent target clinical immunosuppression report development specific orally active inhibitor jak3 cp- significantly prolonged survival murine model heart transplantation cynomolgus monkeys receiving kidney transplants cp- treatment associated hypertension hyperlipidemia lymphoproliferative disease basis preclinical results believe jak3 blockade cp- potential therapeutically desirable immunosuppression human organ transplantation clinical settings
